The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
- PMID: 12049574
- DOI: 10.1001/archopht.120.6.701
The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma
Abstract
Background: Primary open-angle glaucoma (POAG) is one of the leading causes of blindness in the United States and worldwide. Three to 6 million people in the United States are at increased risk for developing POAG because of elevated intraocular pressure (IOP), or ocular hypertension. There is no consensus on the efficacy of medical treatment in delaying or preventing the onset of POAG in individuals with elevated IOP. Therefore, we designed a randomized clinical trial, the Ocular Hypertension Treatment Study.
Objective: To determine the safety and efficacy of topical ocular hypotensive medication in delaying or preventing the onset of POAG.
Methods: A total of 1636 participants with no evidence of glaucomatous damage, aged 40 to 80 years, and with an IOP between 24 mm Hg and 32 mm Hg in one eye and between 21 mm Hg and 32 mm Hg in the other eye were randomized to either observation or treatment with commercially available topical ocular hypotensive medication. The goal in the medication group was to reduce the IOP by 20% or more and to reach an IOP of 24 mm Hg or less.
Main outcome measures: The primary outcome was the development of reproducible visual field abnormality or reproducible optic disc deterioration attributed to POAG. Abnormalities were determined by masked certified readers at the reading centers, and attribution to POAG was decided by the masked Endpoint Committee.
Results: During the course of the study, the mean +/- SD reduction in IOP in the medication group was 22.5% +/- 9.9%. The IOP declined by 4.0% +/- 11.6% in the observation group. At 60 months, the cumulative probability of developing POAG was 4.4% in the medication group and 9.5% in the observation group (hazard ratio, 0.40; 95% confidence interval, 0.27-0.59; P<.0001). There was little evidence of increased systemic or ocular risk associated with ocular hypotensive medication.
Conclusions: Topical ocular hypotensive medication was effective in delaying or preventing the onset of POAG in individuals with elevated IOP. Although this does not imply that all patients with borderline or elevated IOP should receive medication, clinicians should consider initiating treatment for individuals with ocular hypertension who are at moderate or high risk for developing POAG.
Comment in
-
Ocular hypertension treatment study results could be misconstrued.Arch Ophthalmol. 2003 Jul;121(7):1070; author reply 1070. doi: 10.1001/archopht.121.7.1070-a. Arch Ophthalmol. 2003. PMID: 12860828 No abstract available.
-
Ocular hypertension treatment study.Arch Ophthalmol. 2004 Jul;122(7):1088-9; author reply 1089. doi: 10.1001/archopht.122.7.1088. Arch Ophthalmol. 2004. PMID: 15249390 No abstract available.
Similar articles
-
The Ocular Hypertension Treatment Study: topical medication delays or prevents primary open-angle glaucoma in African American individuals.Arch Ophthalmol. 2004 Jun;122(6):813-20. doi: 10.1001/archopht.122.6.813. Arch Ophthalmol. 2004. PMID: 15197055 Clinical Trial.
-
Delaying treatment of ocular hypertension: the ocular hypertension treatment study.Arch Ophthalmol. 2010 Mar;128(3):276-87. doi: 10.1001/archophthalmol.2010.20. Arch Ophthalmol. 2010. PMID: 20212196 Free PMC article. Clinical Trial.
-
The Ocular Hypertension Treatment Study: baseline factors that predict the onset of primary open-angle glaucoma.Arch Ophthalmol. 2002 Jun;120(6):714-20; discussion 829-30. doi: 10.1001/archopht.120.6.714. Arch Ophthalmol. 2002. PMID: 12049575 Clinical Trial.
-
Topical bimatoprost: a review of its use in open-angle glaucoma and ocular hypertension.Drugs Aging. 2002;19(3):231-48. doi: 10.2165/00002512-200219030-00008. Drugs Aging. 2002. PMID: 12027782 Review.
-
What We Have Learned From the Ocular Hypertension Treatment Study.Am J Ophthalmol. 2018 May;189:xxiv-xxvii. doi: 10.1016/j.ajo.2018.02.016. Epub 2018 Mar 1. Am J Ophthalmol. 2018. PMID: 29501371 Free PMC article. Review.
Cited by
-
Harnessing the power of longitudinal medical imaging for eye disease prognosis using Transformer-based sequence modeling.NPJ Digit Med. 2024 Aug 16;7(1):216. doi: 10.1038/s41746-024-01207-4. NPJ Digit Med. 2024. PMID: 39152209 Free PMC article.
-
Real-Life Study on the Efficacy and Tolerance of a Preservative-Free Surfactant-Free Latanoprost Eye Drop in Patients with Glaucoma.Ophthalmol Ther. 2024 Aug 12. doi: 10.1007/s40123-024-01013-x. Online ahead of print. Ophthalmol Ther. 2024. PMID: 39133376
-
Lycium barbarum glycopeptide promotes neuroprotection in ET-1 mediated retinal ganglion cell degeneration.J Transl Med. 2024 Aug 5;22(1):727. doi: 10.1186/s12967-024-05526-8. J Transl Med. 2024. PMID: 39103918 Free PMC article.
-
CRISPR-CasRx-mediated disruption of Aqp1/Adrb2/Rock1/Rock2 genes reduces intraocular pressure and retinal ganglion cell damage in mice.Nat Commun. 2024 Jul 30;15(1):6395. doi: 10.1038/s41467-024-50050-4. Nat Commun. 2024. PMID: 39080269 Free PMC article.
-
Omidenepag Isopropyl 0.002% versus Latanoprost 0.005% in Open-Angle Glaucoma/Ocular Hypertension: The Randomized Phase III PEONY Trial.Clin Ophthalmol. 2024 Jul 16;18:2093-2106. doi: 10.2147/OPTH.S465369. eCollection 2024. Clin Ophthalmol. 2024. PMID: 39051019 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical